These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35203384)

  • 21. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.
    Gong C; Fujino K; Monteiro LJ; Gomes AR; Drost R; Davidson-Smith H; Takeda S; Khoo US; Jonkers J; Sproul D; Lam EW
    Oncogene; 2015 Sep; 34(39):5012-24. PubMed ID: 25531315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional inhibition of F11 receptor (F11R/junctional adhesion molecule-A/JAM-A) activity by a F11R-derived peptide in breast cancer and its microenvironment.
    Bednarek R; Selmi A; Wojkowska D; Karolczak K; Popielarski M; Stasiak M; Salifu MO; Babinska A; Swiatkowska M
    Breast Cancer Res Treat; 2020 Jan; 179(2):325-335. PubMed ID: 31650345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression.
    Smith YE; Wang G; Flynn CL; Madden SF; MacEneaney O; Cruz RGB; Richards CE; Jahns H; Brennan M; Cremona M; Hennessy BT; Sheehan K; Casucci A; Sani FA; Hudson L; Fay J; Vellanki SH; O'Flaherty S; Devocelle M; Hill ADK; Brennan K; Sukumar S; Hopkins AM
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Junctional Adhesion Molecules in Cancer: A Paradigm for the Diverse Functions of Cell-Cell Interactions in Tumor Progression.
    Lauko A; Mu Z; Gutmann DH; Naik UP; Lathia JD
    Cancer Res; 2020 Nov; 80(22):4878-4885. PubMed ID: 32816855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma.
    Kakuki T; Kurose M; Takano K; Kondoh A; Obata K; Nomura K; Miyata R; Kaneko Y; Konno T; Takahashi S; Hatakeyama T; Kohno T; Himi T; Kojima T
    Oncotarget; 2016 Jun; 7(23):33887-900. PubMed ID: 27036044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The transcriptional regulation of SOX2 on FOXA1 gene and its application in diagnosis of human breast and lung cancers.
    Li X; Chen S; Sun T; Xu Y; Chen Y; Liu Y; Xiang R; Li N
    Clin Lab; 2014; 60(6):909-18. PubMed ID: 25016694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
    Jing X; Liang H; Hao C; Hongxia L; Cui X
    Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The activation of EP300 by F11R leads to EMT and acts as a prognostic factor in triple-negative breast cancers.
    Li CH; Fang CY; Chan MH; Lu PJ; Ger LP; Chu JS; Chang YC; Chen CL; Hsiao M
    J Pathol Clin Res; 2023 May; 9(3):165-181. PubMed ID: 36782375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.
    Wolf I; Bose S; Williamson EA; Miller CW; Karlan BY; Koeffler HP
    Int J Cancer; 2007 Mar; 120(5):1013-22. PubMed ID: 17163418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Throughput Chemical Screening Reveals Multiple Regulatory Proteins on FOXA1 in Breast Cancer Cell Lines.
    Wang S; Singh SK; Katika MR; Lopez-Aviles S; Hurtado A
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
    De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
    BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1.
    Shen SQ; Huang LS; Xiao XL; Zhu XF; Xiong DD; Cao XM; Wei KL; Chen G; Feng ZB
    Oncol Rep; 2017 Jul; 38(1):368-376. PubMed ID: 28534958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-495 induces breast cancer cell migration by targeting JAM-A.
    Cao M; Nie W; Li J; Zhang Y; Yan X; Guan X; Chen X; Zen K; Zhang CY; Jiang X; Hou D
    Protein Cell; 2014 Nov; 5(11):862-72. PubMed ID: 25070379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
    McCune K; Bhat-Nakshatri P; Thorat MA; Nephew KP; Badve S; Nakshatri H
    Cancer Res; 2010 Jan; 70(2):685-96. PubMed ID: 20068169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
    Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
    Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
    Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAM-A expression positively correlates with poor prognosis in breast cancer patients.
    McSherry EA; McGee SF; Jirstrom K; Doyle EM; Brennan DJ; Landberg G; Dervan PA; Hopkins AM; Gallagher WM
    Int J Cancer; 2009 Sep; 125(6):1343-51. PubMed ID: 19533747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOXA1 Induces E-Cadherin Expression at the Protein Level via Suppression of Slug in Epithelial Breast Cancer Cells.
    Anzai E; Hirata K; Shibazaki M; Yamada C; Morii M; Honda T; Yamaguchi N; Yamaguchi N
    Biol Pharm Bull; 2017; 40(9):1483-1489. PubMed ID: 28867731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.